Why the study?
What are the predictors of fibrinolytic therapy use in patients with acute myocardial infarction?
What are the predictors of fibrinolytic therapy use in patients with acute myocardial infarction?
Older age, female sex, longer pre-hospital time, and previous myocardial infarction are associated with a lower likelihood of receiving fibrinolytic therapy for acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Lower fibrinolytic use in older AMI patients may reflect disparities or appropriate selection; cohort data leave open the need for eligibility audits.
Age-related use of fibrinolytic therapy in acute myocardial infarction was studied for patients admitted to the intensive care unit in four hospitals comprising 10% of the national hospital bed capacity in Norway. Altogether, 446 patients were included. All had validated acute myocardial infarction or acute ischaemic coronary heart disease treated with fibrinolytic medication. The fibrinolytic treatment rate decreased linearly from 74% among patients younger than 50 years to 15% among those older than 80 (p < 0.0001). In a multiple logistic regression, low age, short pre-hospital time and no previous myocardial infarction strongly predicted use of fibrinolytic therapy (p < 0.0001), and male sex was a significant predictor for use of fibrinolytic therapy (p = 0.01).
No takes yet. Share an insight, caveat, or question.
Kjell I. Pettersen (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: